When: FY27 Q1 print (late August/mid-September 2026) meeting upgrade criteria

Then: Scale to 3.0% per catalyst framework

HOLD

• RSI bearish divergence: prior peak August 14th at 71.12, current reading at 71.03 has failed to make new high in price at same resistance level
• Volume declining to 4.79M from 14.5M structural breakout day, suggesting overhead supply absorbing bid rather than institutional accumulation
• Forward P/E of 14.36x driven by forward EPS of $6.41 implying 72% EPS jump from TTM EPS of $3.73, but this jump is entirely tax-rate dependent (31.4% effective tax rate normalizing)
• Alternative EPS of $5.20 to $5.50 if tax normalizes to 17-20% would put forward P/E at 16 to 18x (fair value for med-device with 9.84% ROE)
• Litigation verdict of $88M is compensatory only with unknown aggregate portfolio exposure, punitive damages, and potential goodwill impairment given $52.7B goodwill against $93B total assets
• Macro headwinds: 30-year Treasury at 19-year high, US debt approaching $40 trillion, Fed pricing 85% probability of zero cuts in 2026, 3.18% dividend yield not compelling vs comparable bond returns
• Stop-loss at $83.43 (50 SMA) equals 9.4% downside which is too loose for defensive position; tighter stop of $86.50 to $87.21 recommended (5 to 6% risk)
• Stock up 25.9% from May low; easy money already made, remaining upside harder and statistically less rewarding
• Breakout add threshold requires sustained confirmation above $93.50, not single-day print; current plan sets too low a bar
• Conservative plan: hold core, do not add at $92, deploy on pullback to $88 to $89, cap new exposure at 2.0% until litigation and tax normalization verified
• ROE of 9.84% and PEG of 1.8 suggest mediocre fundamentals not screaming value at current levels

→ vs aggressive: RSI 71.03 is dismissed as 'barely over' threshold but ignores prior peak at 71.12 on August 14th; this is textbook bearish RSI divergence when oscillator fails to make new high at same resistance, not 'lazy analysis'

→ vs aggressive: Volume argument is backwards: 14.5M was confirmation of breakout above 200 SMA (fresh institutional bid), not baseline for current 4.79M which represents thin bid at overhead supply, not accumulation

→ vs aggressive: Forward P/E of 14.36x is only cheap under most optimistic tax assumption; actual normalized EPS likely $5.20 to $5.50 putting P/E at 16 to 18x, which is fair value given 9.84% ROE and declining margins

→ vs aggressive: Litigation $88M verdict framed as 'two weeks of free cash flow' ignores unknown aggregate portfolio exposure, potential punitive damages, and goodwill impairment risk against $52.7B in goodwill

→ vs aggressive: Macro framing ignores 30-year Treasury at 19-year high and Fed pricing 85% probability of zero cuts; 3.18% dividend yield not compelling vs comparable risk-adjusted bond returns

→ vs aggressive: FOMO argument about missing breakout above $93.50 is not analysis; asymmetry strongly favors waiting for confirmed pullback to $88 to $89 over chasing 25.9% move from May low

→ vs aggressive: Breakout add trigger at single close above $93.50 on volume approaching 14.5M sets too low a bar; one-day breakouts fail more often than they succeed for defensive portfolios

HOLD

• Existing core positions should be held; dividend is safe and balance sheet is improving
• New capital should wait for pullback to $88.50-$89.70 zone with RSI cooling toward 55-60, OR confirmed 2-3 day close above $93.50 on volume above 7 million shares
• Forward EPS estimated at $5.50-$5.80, giving forward P/E of 16-17x (fair value, not deep value, not expensive)
• Litigation risk is real but bounded; monitoring posture correct until next 10-Q clarifies reserve adequacy
• Position sizing: initial add 0.75%, cap at 2.5% total exposure (lower end of 2.5-3.0% range)
• Stop-loss on new adds should be $85.00-$86.00 (below 200 SMA at $88.57)
• RSI currently at 71.03 versus prior August 14 peak of 71.12 (marginal, warning not signal)
• Price tested $93.07 intraday; RSI rolled over at same level twice at resistance
• Breakout confirmation requires 2-3 daily closes above $93.50 with volume above 7 million shares
• Trend structurally intact with price above 10 EMA, 200 SMA, and 50 SMA approaching golden cross
• MACD histogram expanding; sector tape constructive
• Forward P/E aggressive estimate of 14.36x uses optimistic 15% tax rate; normalized rate of 18-20% yields P/E of 16-17x
• ROE of 9.84% and $52 billion goodwill support fair-value framing, not momentum
• Beta of 0.57 confirms defensive profile
• Defensive secular tailwinds exist in PFA, diabetes, and structural heart

→ vs aggressive: RSI setup at 71.03 versus prior 71.12 is not lazy analysis—dismissing it as bias is intellectually sloppy; if RSI fails to confirm next push above $93.50, that becomes meaningful information about trend character

→ vs aggressive: Volume argument flawed: declining volume at resistance after 26% move is a warning pattern that precedes multi-week consolidation or failed break; institutional accumulation requires volume confirmation at resistance, not just at initial breakout

→ vs aggressive: Valuation 'coiled spring' framing uses most optimistic sell-side assumptions; forward EPS of $6.41 assumes 15% tax rate, but normalization to 18-20% yields $5.30-$5.60; forward P/E is 16-17x, not 14.36x

→ vs conservative: RSI divergence overstated; 1-point differential (71.12 to 71.03) is noise, not meaningful divergence requiring the oscillator to fail to confirm new highs

→ vs conservative: Volume argument overreach; quality large-caps can grind higher on declining volume for weeks before resolving; declining volume is monitoring information, not definitive warning that breakout will fail

→ vs conservative: Macro case overstated; 30-year at 19-year high and zero Fed cuts, but sector performance contradicts thesis—Stryker +3.8%, Edwards +14% in 3 months, CONMED +16% in a month on raised guidance, Boston Scientific -50%; med-tech being bought selectively is rotation into defensive growth with proven demand visibility, not rotation away from risk

→ vs conservative: Stop-loss at 9.4% is too loose but $86.50 is too tight given 200 SMA at $88.57 acting as support; middle ground of $85-$86 is correct

→ vs conservative: Demand for successful retest of $93.50 as new support is excessive; waiting for full retest means missing the meat of the move

→ vs conservative: 2.0% position cap is too restrictive for a defensive core holding with ballast role; 2.5-3.0% cap more appropriate